Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review

Sergio Bracarda, Camillo Porta, Roberto Sabbatini, Licia Rivoltini

Research output: Contribution to journalArticle

Abstract

In the so-called "antiangiogenic era" of recent years, a number of targeted therapies have been approved for the treatment of metastatic renal cell carcinoma (mRCC). Emerging information about the immunological features of mRCC and the immunomodulating properties of antiangiogenic agents, one of the standard treatments for mRCC, indicates that a more rational design of potentially synergistic combinations should be pursued. Indeed, immunotherapy has undergone a resurgence in clinical practice. In this narrative review, we discuss the immunological features of mRCC and the potential interactions that antiangiogenic agents may also exert on host immunity and tumor immunogenicity, possibly working on both sides of this complex cross-talk. Hence, the recall to Gianus, the ancient two-faced Roman God who was looking both at the future and the past. Treatment strategies will be also critically discussed.
Original languageEnglish
Pages (from-to)149-157
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume139
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Antiangiogenic agents
  • Checkpoint inhibitors
  • Immunotherapy
  • Metastatic renal cell carcinoma
  • Angiogenesis Inhibitors/*therapeutic use
  • Carcinoma, Renal Cell/blood supply/*drug therapy/pathology
  • Humans
  • Immunologic Factors/*therapeutic use
  • Immunomodulation
  • Immunotherapy/*methods
  • Kidney Neoplasms/blood supply/*drug therapy/secondary
  • Neovascularization, Pathologic/*prevention & control

Fingerprint Dive into the research topics of 'Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review'. Together they form a unique fingerprint.

  • Cite this